Clinical Trials Logo

Clinical Trial Summary

The French guidelines for the use of Rifamycine eye drops in delivery room to prevent neonatal conjunctivitis have been actualized. Only newborns exposed to risk factors of conjunctivitis should be treated, compared to previous guidelines, treating all newborns. currently, there are no data describing risk factors for neonatal conjunctivitis. This study evaluated the incidence of conjunctivitis with or without Rifamycine eye drops treatment in the delivery room. Then risk factors for neonatal conjunctivitis where analyzed.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03528915
Study type Observational
Source Centre Hospitalier Universitaire, Amiens
Contact
Status Completed
Phase
Start date September 9, 2015
Completion date July 24, 2016

See also
  Status Clinical Trial Phase
Completed NCT00000120 - Clinical Trial of Eye Prophylaxis in the Newborn Phase 3